查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1908155

分子诊断市场规模、份额和趋势分析报告：按产品、检测地点、技术、应用、地区和细分市场预测，2026-2033年

Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test Location, By Technology, By Application, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 270 Pages | 商品交期: 2-10个工作天内

价格

分子诊断市场概述

2025年全球分子诊断市场规模估计为188.5亿美元，预计2033年将达255.9亿美元。

预计从 2026 年到 2033 年，该行业将以 4.06% 的复合年增长率成长。推动这一增长的关键因素包括技术的持续进步、人口老化的加剧以及对准确且高效的基因检测解决方案日益增长的需求。

此外，由于人们对便利的自我诊断工具的需求以及患者对快速检测结果益处的认识不断提高，照护现场检测 (POC) 的普及也推动了公司创新和新检测产品的推出。

随着就地检验(POCT) 需求的持续成长，一些新兴趋势正在重塑市场格局，并强化其在分子诊断领域的角色。其中一个主要变化是临床科室日益专业化，推动了不同医疗应用的专用 POCT 解决方案的开发。这与医疗保健分散化的大趋势不谋而合，使得小规模医疗机构也能更容易获得先进的诊断技术。因此，POCT 系统在设计上更加重视准确性、速度和成本效益。

市场相关人员正积极开发创新即时检测 (POCT) 产品，以掌握新兴机会。例如，2024 年 11 月，德克萨斯州启动了试验计画，重点推广 HPV 自取样筛检，旨在扩大服务不足地区子宫颈癌检测的覆盖范围。该计画与德克萨斯大学 MD 安德森癌症中心合作，在 Su Clinica 联邦认证医疗中心 (FQHC) 开展，旨在评估自取样筛检在实际应用中的有效性。该计画采用 FDA核准的BD Onclarity HPV 检测方法，以消除子宫颈癌筛检在地理和社会经济方面的障碍，并探索改善医疗服务提供的策略。透过展示自取样方法在资源匮乏环境中的实用性，该计画有助于更广泛地采用 POCT 解决方案，并增强医疗服务提供者和政策制定者之间的信任。

Sigma-Aldrich 和 QIAGEN 等公司正在利用 TMA 和 LAMP 等先进技术进行肿瘤诊断，而次世代定序(NGS) 由于其在基因组研究中的广泛应用，仍然是成长最快的领域之一。 Thermo Fisher 的 5500x1 基因分析仪和 Illumina 的 NextSeq CN500 等新型系统的推出，以及多重 PCR 和即时PCR平台（例如 QIAGEN 的 EpiTect Methyl II PCR）的日益普及，都在持续推动市场成长。

透过密集的研发投入和策略合作，领先的製造商正在拓展其qPCR和疾病特异性诊断测试的产品组合。肿瘤学和传染病检查领域的显着进展包括罗氏的Cobas HPV检测和Sepede的GeneXpert结核病检测。 FISH和ELISA等技术的应用也不断增加，从而增强了诊断的多样性并拓宽了临床应用。

感染疾病的持续肆虐不断推动着对快速分子诊断的需求。在新冠肺炎疫情期间，RT-PCR和定序在病毒检测中发挥了关键作用，这得益于Biosciences公司的Lyo-Ready RT-qPCR混合液和Novacit公司的RUO冠状病毒检测套组等创新技术的推动。随着芝加哥大学和西北大学研究人员开发的2024血液检测等突破性技术的出现，人们对液态生物检体技术的兴趣也日益浓厚。此检测技术能够透过循环DNA片段检测癌症。

分子诊断工具对于早期识别与慢性疾病相关的生物标记至关重要，从而能够及时介入并改善患者预后。根据美国疾病管制与预防中心（CDC）估计，到2024年，将有1.29亿美国人患有至少一种主要慢性疾病，包括心臟病、癌症、糖尿病、肥胖和高血压。此外，42%的人口将患有两种或两种以上慢性疾病，12%的人口将患有五种或五种以上慢性疾病。这些疾病约占美国每年4.1兆美元医疗费用支出的90%。随着慢性疾病盛行率的持续上升，对有效诊断和管理解决方案的需求也将持续增长。癌症、心血管疾病、神经系统疾病和遗传性疾病病例的增加预计将进一步推动市场成长。

外部资金对分子诊断研究的投入在加速产品创新方面也扮演关键角色。 2025年9月，韩国Seegene公司与Springer Nature合作推出了2025-2026年度Nature Awards MDx Impact Grants项目，为针对抗药性尿道感染的诊断开发提供资金支持和综合征PCR检测服务。同样，2023年4月，Promega公司拨款1.5万美元，用于支持使用qPCR技术的学术研究。鑑于感染疾病的演变和抗生素抗药性的日益增强，持续更新分子诊断检测项目至关重要。世界卫生组织于2020年1月宣布新冠肺炎疫情为全球卫生紧急事件，这场疫情凸显了诊断技术快速发展的重要性。

目录

第一章调查方法和范围

第二章执行摘要

第三章 分子诊断的变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关及配套市场展望
  • 市场动态
  • 分子诊断分析工具
    • 产业分析：波特五力模型
    • PESTEL 分析

4. 分子诊断市场：产品細項分析，2021-2033年

  • 定义和范围
  • 按产品分類的市占率分析（2025 年和 2033 年）
  • 2021-2033年分子诊断市场（依产品划分）
  • 市场规模、预测与趋势分析，2021-2033年

5. 分子诊断市场：依检测地点分類的细分市场分析，2021-2033年

  • 定义和范围
  • 按测试地点分類的市场份额分析（2025 年和 2033 年）
  • 2021-2033年全球分子诊断市场（依检测地点划分）
  • 市场规模、预测与趋势分析，2021-2033年

6. 分子诊断市场：依技术分類的细分市场分析，2021-2033年

  • 定义和范围
  • 按技术分類的市场份额分析（2025 年和 2033 年）
  • 全球分子诊断市场（依技术划分），2021-2033年
  • 市场规模、预测与趋势分析，2021-2033年

7. 分子诊断市场：按应用领域分類的细分市场分析，2021-2033年

  • 定义和范围
  • 按应用领域分類的市场份额分析（2025 年和 2033 年）
  • 全球分子诊断市场依应用领域划分，2021-2033年
  • 市场规模、预测与趋势分析，2021-2033年

第八章 分子诊断市场：区域估算与趋势分析

  • 区域仪錶板
  • 市场规模、预测与趋势分析，2021-2033年
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 比利时
    • 瑞士
    • 荷兰
    • 葡萄牙
    • 丹麦
    • 瑞典
    • 土耳其
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 泰国
    • 越南
    • 印尼
    • 韩国
  • 拉丁美洲
    • 巴西
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 阿根廷
    • 厄瓜多
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 企业市场占有率分析（2025）
  • 主要企业简介
    • BD
    • BIOMERIEUX
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic Inc.（Gen Probe）
    • Illumina, Inc.
    • Grifols
    • QIAGEN
    • F. Hoffmann-La Roche, Ltd.
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Seegene Inc
    • EliTechGroup
    • CERTEST BIOTEC
Product Code: 978-1-68038-086-6

Molecular Diagnostics Market Summary

The global molecular diagnostics market size was estimated at USD 18.85 billion in 2025 and is projected to reach USD 25.59 billion by 2033, growing at a CAGR of 4.06% from 2026 to 2033. Key drivers of this growth include ongoing technological advancements, a steadily aging population, and rising demand for precise, efficient genetic testing solutions.

In addition, the increasing adoption of Point-of-Care (POC) testing driven by the need for convenient self-diagnostic tools and greater patient awareness of the benefits of rapid results is encouraging companies to innovate and introduce new testing products.

As demand for point-of-care testing (POCT) continues to grow, several emerging trends are reshaping the market and strengthening its role within molecular diagnostics. One major shift is the increasing specialization of clinical departments, prompting the development of tailored POCT solutions for diverse medical applications. This aligns with the broader movement toward healthcare decentralization, where advanced diagnostic technologies are becoming more accessible in smaller facilities. As a result, POCT systems are being designed with greater precision, speed, and cost-efficiency.

Market players are actively developing innovative POCT products to capitalize on new opportunities. For example, in November 2024, Texas launched a pilot program focused on self-collected HPV screening to expand access to cervical cancer testing in underserved regions. Conducted at Su Clinica Federally Qualified Health Center (FQHC) in collaboration with The University of Texas MD Anderson Cancer Center, the initiative aims to evaluate the real-world effectiveness of self-collection screening. Using the FDA-approved BD Onclarity HPV Assay, the program addresses geographic and socioeconomic barriers to cervical cancer detection and examines strategies to improve healthcare delivery. By demonstrating the practicality of self-collection methods in resource-limited environments, the program supports broader adoption of POCT solutions and reinforces trust among providers and policymakers.

Companies such as Sigma Aldrich and QIAGEN are leveraging advanced technologies like TMA and LAMP for tumor diagnostics, while next-generation sequencing (NGS) remains one of the fastest-growing segments due to its widespread use in genomic research. The introduction of new systems-such as Thermo Fisher's 5500x1 genetic analyzer and Illumina's NextSeq CN500-along with the rising use of multiplex and real-time PCR platforms (e.g., QIAGEN's EpiTect Methyl II PCR) continues to stimulate market expansion.

Through focused R&D and strategic collaborations, leading manufacturers are broadening their portfolios of qPCR and disease-specific diagnostic tests. Notable advancements in oncology and infectious disease testing include Roche's Cobas HPV assay and Cepheid's GeneXpert Xpert assay for tuberculosis. Adoption of technologies such as FISH and ELISA is also increasing, enhancing diagnostic diversity and expanding clinical applications.

The persistent burden of infectious diseases continues to elevate the need for rapid molecular diagnostics. During the COVID-19 pandemic, RT-PCR and sequencing played a crucial role in virus detection, supported by innovations such as Biosciences' Lyo-Ready RT-qPCR mix and Novacyt's RUO coronavirus assay. Interest in liquid biopsy techniques is also rising, driven by breakthroughs like the 2024 blood test developed by researchers at the University of Chicago and Northwestern University, capable of detecting cancer through circulating DNA fragments.

Molecular diagnostic tools are essential for identifying biomarkers linked to chronic diseases at early stages, enabling timely interventions and improved patient outcomes. According to the CDC, an estimated 129 million Americans were living with at least one major chronic condition in 2024, including heart disease, cancer, diabetes, obesity, or hypertension. Furthermore, 42% of the population manages two or more chronic illnesses, while 12% face five or more. These conditions account for roughly 90% of the nation's annual USD 4.1 trillion healthcare expenditure. With chronic disease prevalence steadily rising, the demand for effective diagnostic and management solutions will continue to climb. Growing cases of cancer, cardiovascular, neurological, and genetic disorders are expected to further drive market growth.

External funding for molecular diagnostics research also plays a vital role in accelerating product innovation. In September 2025, South Korea's Seegene Inc., in collaboration with Springer Nature, launched the 2025-2026 "Nature Awards MDx Impact Grants," offering financial support and access to syndromic PCR assays for developing diagnostics targeting antibiotic-resistant urinary tract infections. Likewise, in April 2023, Promega Corporation awarded USD 15,000 to support academic research using qPCR. Continuous updates to molecular diagnostic test menus are essential, given the evolving nature of infectious diseases and increasing antimicrobial resistance. The COVID-19 outbreak-declared a global health emergency by the WHO in January 2020-underscored the importance of rapid advancements in diagnostic technologies.

Global Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular diagnostics market report based on product, test location, technology, application, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Regards
  • Others
  • Test Location Outlook (Revenue, USD Million; 2021 - 2033)
  • Point of care
  • Self test or OTC
  • Central laboratories
  • Technology Outlook (Revenue, USD Million; 2021 - 2033)
  • Polymerase chain reaction (PCR)
    • PCR, by Procedure
    • Nucleic Acid Extraction
    • Others
    • PCR, by Type
    • Multiplex PCR
    • Other PCR
    • PCR, by Product
    • Instruments
    • Reagents
    • Others
  • In Situ Hybridization (ISH)
    • Instruments
    • Reagents
    • Others
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Instruments
    • Reagents
    • Others
  • Chips and Microarrays
    • Instruments
    • Reagents
    • Others
  • Mass Spectrometry
    • Instruments
    • Reagents
    • Others
  • Transcription Mediated Amplification (TMA)
    • Instruments
    • Reagents
    • Others
  • Others
    • Instruments
    • Reagents
    • Others
  • Application Outlook (Revenue, USD Million; 2021 - 2033)
  • Oncology
    • Breast Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Cervical
    • Kidney
    • Liver
    • Blood
    • Lung
    • Other
  • Pharmacogenomics
  • Infectious disease
    • MRSA
    • Clostridium difficile
    • Vancomycin-resistant enterococci
    • Carbapenem-resistant bacteria testing
    • Flu
    • Respiratory syncytial virus (RSV)
    • Candida
    • Tuberculosis and drug-resistant TB
    • Meningitis
    • Gastro-intestinal panel testing
    • Chlamydia
    • Gonorrhea
    • HIV
    • Hepatitis C
    • Hepatitis B
    • Other Infectious Diseases
  • Genetic testing
    • Newborn screening
    • Predictive and presymptomatic testing
    • Others
  • Neurological disease
  • Cardiovascular disease
  • Microbiology
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
    • Portugal
    • Switzerland
    • Belgium
    • Turkey
    • Netherlands
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
    • Malaysia
    • Indonesia
    • Vietnam
  • Latin America
    • Brazil
    • Argentina
    • Colombia
    • Peru
    • Ecuador
    • Chile
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End Use
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Molecular Diagnostics Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Introduction of technologically advanced products
      • 3.2.1.2. Increase in demand for point-of-care Testing
      • 3.2.1.3. Growing prevalence of target diseases
      • 3.2.1.4. Increasing external funding for R&D
      • 3.2.1.5. Outbreak of COVID-19
      • 3.2.1.6. Increase in geriatric population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of ambiguous regulatory framework
      • 3.2.2.2. High prices of molecular diagnostics tests
  • 3.3. Molecular Diagnostics Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Molecular Diagnostics Market: Segment Analysis, By Product, 2021 - 2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Product Market Share Analysis, 2025 & 2033
  • 4.3. Molecular Diagnostics Market, by Product, 2021 to 2033
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 4.4.1. Instruments
      • 4.4.1.1. Instruments market, 2021 - 2033 (USD Million)
    • 4.4.2. Reagents
      • 4.4.2.1. Reagents market, 2021 - 2033 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Molecular Diagnostics Market: Segment Analysis, By Test Location, 2021 - 2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. Test Location Market Share Analysis, 2025 & 2033
  • 5.3. Global Molecular Diagnostics Market, by Test Location, 2021 to 2033
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 5.4.1. Point of care
      • 5.4.1.1. Point of care market, 2021 - 2033 (USD Million)
    • 5.4.2. Self test or OTC
      • 5.4.2.1. Self test or OTC market, 2021 - 2033 (USD Million)
    • 5.4.3. Central laboratories
      • 5.4.3.1. Central laboratories market, 2021 - 2033 (USD Million)

Chapter 6. Molecular Diagnostics Market: Segment Analysis, By Technology, 2021 - 2033 (USD Million)

  • 6.1. Definition and Scope
  • 6.2. Technology Market Share Analysis, 2025 & 2033
  • 6.3. Global Molecular Diagnostics Market, by Technology, 2021 to 2033
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 6.4.1. PCR
      • 6.4.1.1. PCR market, 2021 - 2033 (USD Million)
      • 6.4.1.2. By procedure
        • 6.4.1.2.1. Nucleic acid extraction
          • 6.4.1.2.1.1. Nucleic acid extraction market, 2021 - 2033 (USD Million)
        • 6.4.1.2.2. Others
          • 6.4.1.2.2.1. Others market, 2021 - 2033 (USD Million)
      • 6.4.1.3. By type
        • 6.4.1.3.1. Multiplex
          • 6.4.1.3.1.1. Multiplex market, 2021 - 2033 (USD Million)
        • 6.4.1.3.2. Others
          • 6.4.1.3.2.1. Others market, 2021 - 2033 (USD Million)
      • 6.4.1.4. By product
        • 6.4.1.4.1. Instruments
          • 6.4.1.4.1.1. Instruments market, 2021 - 2033 (USD Million)
        • 6.4.1.4.2. Reagents
          • 6.4.1.4.2.1. Reagents market, 2021 - 2033 (USD Million)
        • 6.4.1.4.3. Others
          • 6.4.1.4.3.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.2. ISH
      • 6.4.2.1. ISH market, 2021 - 2033 (USD Million)
      • 6.4.2.2. Instruments
        • 6.4.2.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.2.3. Reagents
        • 6.4.2.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.2.4. Others
        • 6.4.2.4.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.3. INAAT
      • 6.4.3.1. INAAT market, 2021 - 2033 (USD Million)
      • 6.4.3.2. Instruments
        • 6.4.3.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.3.3. Reagents
        • 6.4.3.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.3.4. Others
        • 6.4.3.4.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.4. Chips and microarrays
      • 6.4.4.1. Chips and microarrays market, 2021 - 2033 (USD Million)
      • 6.4.4.2. Instruments
        • 6.4.4.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.4.3. Reagents
        • 6.4.4.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.4.4. Others
        • 6.4.4.4.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.5. Mass spectrometry
      • 6.4.5.1. Mass spectrometry market, 2021 - 2033 (USD Million)
      • 6.4.5.2. Instruments
        • 6.4.5.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.5.3. Reagents
        • 6.4.5.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.5.4. Others
        • 6.4.5.4.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.6. Sequencing
      • 6.4.6.1. Sequencing market, 2021 - 2033 (USD Million)
      • 6.4.6.2. Instruments
        • 6.4.6.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.6.3. Reagents
        • 6.4.6.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.6.4. Others
        • 6.4.6.4.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.7. TMA
      • 6.4.7.1. TMA market, 2021 - 2033 (USD Million)
      • 6.4.7.2. Instruments
        • 6.4.7.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.7.3. Reagents
        • 6.4.7.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.7.4. Others
        • 6.4.7.4.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.8. Others
      • 6.4.8.1. Others market, 2021 - 2033 (USD Million)
      • 6.4.8.2. Instruments
        • 6.4.8.2.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.8.3. Reagents
        • 6.4.8.3.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.8.4. Others
        • 6.4.8.4.1. Others market, 2021 - 2033 (USD Million)

Chapter 7. Molecular Diagnostics Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)

  • 7.1. Definition and Scope
  • 7.2. Application Market Share Analysis, 2025 & 2033
  • 7.3. Global Molecular Diagnostics Market, by Application,2021 to 2033
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 7.4.1. Oncology
      • 7.4.1.1. Oncology market, 2021 - 2033 (USD Million)
      • 7.4.1.2. Breast cancer
        • 7.4.1.2.1. Breast cancer market, 2021 - 2033 (USD Million)
      • 7.4.1.3. Prostate cancer
        • 7.4.1.3.1. Prostate cancer market, 2021 - 2033 (USD Million)
      • 7.4.1.4. Colorectal cancer
        • 7.4.1.4.1. Colorectal cancer market, 2021 - 2033 (USD Million)
      • 7.4.1.5. Cervical
        • 7.4.1.5.1. Cervical market, 2021 - 2033 (USD Million)
      • 7.4.1.6. Kidney
        • 7.4.1.6.1. Kidney market, 2021 - 2033 (USD Million)
      • 7.4.1.7. Liver
        • 7.4.1.7.1. Liver market, 2021 - 2033 (USD Million)
      • 7.4.1.8. Blood
        • 7.4.1.8.1. Blood market, 2021 - 2033 (USD Million)
      • 7.4.1.9. Lung
        • 7.4.1.9.1. Lung market, 2021 - 2033 (USD Million)
      • 7.4.1.10. Other
        • 7.4.1.10.1. Other market, 2021 - 2033 (USD Million)
    • 7.4.2. Pharmacogenomics
      • 7.4.2.1. Pharmacogenomics market, 2021 - 2033 (USD Million)
    • 7.4.3. Infectious disease
      • 7.4.3.1. Infectious disease market, 2021 - 2033 (USD Million)
      • 7.4.3.2. MRSA
        • 7.4.3.2.1. MRSA market, 2021 - 2033 (USD Million)
      • 7.4.3.3. Clostridium difficile
        • 7.4.3.3.1. Clostridium difficile market, 2021 - 2033 (USD Million)
      • 7.4.3.4. Vancomycin-resistant enterococci
        • 7.4.3.4.1. Vancomycin-resistant enterococci market, 2021 - 2033 (USD Million)
      • 7.4.3.5. Carbapenem-resistant bacteria testing
        • 7.4.3.5.1. Carbapenem-resistant bacteria testing market, 2021 - 2033 (USD Million)
      • 7.4.3.6. Flu
        • 7.4.3.6.1. Flu market, 2021 - 2033 (USD Million)
      • 7.4.3.7. Respiratory syncytial virus (RSV)
        • 7.4.3.7.1. Respiratory syncytial virus (RSV) market, 2021 - 2033 (USD Million)
      • 7.4.3.8. Candida
        • 7.4.3.8.1. Candida market, 2021 - 2033 (USD Million)
      • 7.4.3.9. Tuberculosis and drug-resistant TB
        • 7.4.3.9.1. Tuberculosis and drug-resistant TB market, 2021 - 2033 (USD Million)
      • 7.4.3.10. Meningitis
        • 7.4.3.10.1. Meningitis market, 2021 - 2033 (USD Million)
      • 7.4.3.11. Gastro-intestinal panel testing
        • 7.4.3.11.1. Gastro-intestinal panel testing market, 2021 - 2033 (USD Million)
      • 7.4.3.12. Chlamydia
        • 7.4.3.12.1. Chlamydia market, 2021 - 2033 (USD Million)
      • 7.4.3.13. Gonorrhea
        • 7.4.3.13.1. Gonorrhea market, 2021 - 2033 (USD Million)
      • 7.4.3.14. HIV
        • 7.4.3.14.1. HIV market, 2021 - 2033 (USD Million)
      • 7.4.3.15. Hepatitis C
        • 7.4.3.15.1. Hepatitis C market, 2021 - 2033 (USD Million)
      • 7.4.3.16. Hepatitis B
        • 7.4.3.16.1. Hepatitis B market, 2021 - 2033 (USD Million)
      • 7.4.3.17. Other infectious diseases
        • 7.4.3.17.1. Other infectious diseases market, 2021 - 2033 (USD Million)
    • 7.4.4. Genetic testing
      • 7.4.4.1. Genetic testing market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Newborn screening
        • 7.4.4.2.1. Newborn screening market, 2021 - 2033 (USD Million)
      • 7.4.4.3. Predictive and presymptomatic testing
        • 7.4.4.3.1. Predictive and presymptomatic testing market, 2021 - 2033 (USD Million)
      • 7.4.4.4. Others
        • 7.4.4.4.1. Others market, 2021 - 2033 (USD Million)
    • 7.4.5. Neurological disease
      • 7.4.5.1. Neurological disease market, 2021 - 2033 (USD Million)
    • 7.4.6. Cardiovascular disease
      • 7.4.6.1. Cardiovascular disease market, 2021 - 2033 (USD Million)
    • 7.4.7. Microbiology
      • 7.4.7.1. Microbiology market, 2021 - 2033 (USD Million)
    • 7.4.8. Others
      • 7.4.8.1. Others market, 2021 - 2033 (USD Million)

Chapter 8. Molecular Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.4. Spain
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.6. Belgium
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Belgium market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.7. Switzerland
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Switzerland market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.8. Netherlands
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Netherlands market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.9. Portugal
      • 8.4.9.1. Key country dynamics
      • 8.4.9.2. Regulatory framework/ reimbursement structure
      • 8.4.9.3. Competitive scenario
      • 8.4.9.4. Portugal market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.10. Denmark
      • 8.4.10.1. Key country dynamics
      • 8.4.10.2. Regulatory framework/ reimbursement structure
      • 8.4.10.3. Competitive scenario
      • 8.4.10.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.11. Sweden
      • 8.4.11.1. Key country dynamics
      • 8.4.11.2. Regulatory framework/ reimbursement structure
      • 8.4.11.3. Competitive scenario
      • 8.4.11.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.12. Turkey
      • 8.4.12.1. Key country dynamics
      • 8.4.12.2. Regulatory framework/ reimbursement structure
      • 8.4.12.3. Competitive scenario
      • 8.4.12.4. Turkey market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.13. Norway
      • 8.4.13.1. Key country dynamics
      • 8.4.13.2. Regulatory framework/ reimbursement structure
      • 8.4.13.3. Competitive scenario
      • 8.4.13.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. China
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. Thailand
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
      • 8.5.5.5. Key country dynamics
      • 8.5.5.6. Regulatory framework/ reimbursement structure
      • 8.5.5.7. Competitive scenario
      • 8.5.5.8. Malaysia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Vietnam
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Vietnam market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.7. Indonesia
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Indonesia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.8. South Korea
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Colombia
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Colombia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. Chile
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Chile market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Peru
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Peru market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Argentina
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Ecuador
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Ecuador market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Recent Developments & Impact Analysis by Key Market Participants
  • 9.3. Company Market Share Analysis, 2025
  • 9.4. Key Company Profiles
    • 9.4.1. BD
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. BIOMERIEUX
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Bio-Rad Laboratories, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Abbott
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Agilent Technologies, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Danaher
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Hologic Inc. (Gen Probe)
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Illumina, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Grifols
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. QIAGEN
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. F. Hoffmann-La Roche, Ltd.
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Siemens Healthineers AG
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. Sysmex Corporation
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. Seegene Inc
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. EliTechGroup
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. CERTEST BIOTEC
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiativesa

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America molecular diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 5 North America molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 6 North America molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 7 North America molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 8 U.S. molecular diagnostics, by product, 2021 - 2033 (USD Million)
  • Table 9 U.S. molecular diagnostics, by test location, 2021 - 2033 (USD Million)
  • Table 10 U.S. molecular diagnostics, by technology, 2021 - 2033 (USD Million)
  • Table 11 U.S. molecular diagnostics, by application, 2021 - 2033 (USD Million)
  • Table 12 Canada molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 13 Canada molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 14 Canada molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 15 Canada molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 16 Mexico molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 17 Mexico molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 18 Mexico molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 20 Europe molecular diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 22 Europe molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 23 Europe molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 24 Europe molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 25 UK molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 26 UK molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 27 UK molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 28 UK molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 29 Germany molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 30 Germany molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 31 Germany molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 32 Germany molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 33 France molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 34 France molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 35 France molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 36 France molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 37 Spain molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 38 Spain molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 39 Spain molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 40 Spain molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 41 Italy molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 42 Italy molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 43 Italy molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Italy molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 45 Belgium molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 46 Belgium molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 47 Belgium molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Belgium molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 49 Switzerland molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 50 Switzerland molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 51 Switzerland molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Switzerland molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 53 Netherlands molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 54 Netherlands molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 55 Netherlands molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 56 Netherlands molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 57 Portugal molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 58 Portugal molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 59 Portugal molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 60 Portugal molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 61 Denmark molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 62 Denmark molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 63 Denmark molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 64 Denmark molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 65 Sweden molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 66 Sweden molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 67 Sweden molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 68 Sweden molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 69 Turkey molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 70 Turkey molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 71 Turkey molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 72 Turkey molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 73 Norway molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 74 Norway molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 75 Norway molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 76 Norway molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 77 Asia Pacific molecular diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 78 Asia Pacific molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 79 Asia Pacific molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 80 Asia Pacific molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 81 Asia Pacific molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 82 Japan molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 83 Japan molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 84 Japan molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Japan molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 86 China molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 87 China molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 88 China molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 89 China molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 90 India molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 91 India molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 92 India molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 93 India molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 94 Australia molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 95 Australia molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 96 Australia molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 97 Australia molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 98 South Korea molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 99 South Korea molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 100 South Korea molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 101 South Korea molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 102 Malaysia molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 103 Malaysia molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 104 Malaysia molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 105 Malaysia molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 106 Thailand molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 107 Thailand molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 108 Thailand molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 109 Thailand molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 110 Vietnam molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 111 Vietnam molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 112 Vietnam molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 113 Vietnam molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 114 Indonesia molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 115 Indonesia molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 116 Indonesia molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 117 Indonesia molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 118 Latin America molecular diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 119 Latin America molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 120 Latin America molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 121 Latin America molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 122 Latin America molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 123 Brazil molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 124 Brazil molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 125 Brazil molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 126 Brazil molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 127 Colombia molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 128 Colombia molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 129 Colombia molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 130 Colombia molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 131 Chile molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 132 Chile molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 133 Chile molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 134 Chile molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 135 Peru molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 136 Peru molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 137 Peru molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 138 Peru molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 139 Argentina molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 140 Argentina molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 141 Argentina molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 142 Argentina molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 143 Ecuador molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 144 Ecuador molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 145 Ecuador molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 146 Ecuador molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 147 MEA molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 148 MEA molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 149 MEA molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 150 MEA molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 151 South Africa molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 152 South Africa molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 153 South Africa molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 154 South Africa molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 155 Saudi Arabia molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 156 Saudi Arabia molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 157 Saudi Arabia molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 158 Saudi Arabia molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 159 UAE molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 160 UAE molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 161 UAE molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 162 UAE molecular diagnostics market, by application, 2021 - 2033 (USD Million)
  • Table 163 Kuwait molecular diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 164 Kuwait molecular diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 165 Kuwait molecular diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 166 Kuwait molecular diagnostics market, by application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Molecular diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Product and test location segment snapshot
  • Fig. 11 Technology segment snapshot
  • Fig. 12 Application segment snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Molecular diagnostics market value, 2025 (USD Billion)
  • Fig. 15 Market dynamics
  • Fig. 16 Global number of people aged over 60 years or over (thousands) in 2025
  • Fig. 17 Global estimated cancer incidence in different elderly age groups, 2022 (Million)
  • Fig. 18 General trend shifts from laboratory to point-of-care
  • Fig. 19 Incidence of cancer in North America, 2022 - 2050
  • Fig. 20 Incidence of cancer in Europe, 2022 - 2050
  • Fig. 21 Incidence of cancer in Asia Pacific, 2022 - 2050
  • Fig. 22 Incidence of cancer in Latin America, 2022 - 2050
  • Fig. 23 Incidence of cancer in Africa, 2022 - 2050
  • Fig. 24 Incidence of cancer in Oceania, 2022 - 2050
  • Fig. 25 Sources of healthcare financing according to country income, 2020 (%)
  • Fig. 26 Porter's five forces analysis
  • Fig. 27 PESTLE analysis
  • Fig. 28 Molecular diagnostics market: Product outlook and key takeaways
  • Fig. 29 Molecular diagnostics market: Product movement analysis
  • Fig. 30 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Molecular diagnostics market: Technology outlook and key takeaways
  • Fig. 34 Molecular diagnostics market: Technology movement analysis
  • Fig. 35 PCR market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Multiplex PCR market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Other PCR market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 In situ hybridization market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 INAAT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 49 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Chips and microarrays market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 Mass spectrometry market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 59 Sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Transcription mediated amplification (TMA) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 67 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 69 Reagents market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 71 Molecular diagnostics market: Application outlook and key takeaways
  • Fig. 72 Molecular diagnostics market: Application movement analysis
  • Fig. 73 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Breast cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 75 Prostate cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Colorectal cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 77 Cervical cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Kidney canc er market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 79 Liver cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 80 Lung cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 81 Blood cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 82 Other cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 83 Pharmacogenomics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 84 Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 85 Methicillin-resistant staphylococcus aureus (MRSA) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 86 Clostridium difficile market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 87 Vancomycin-resistant enterococci (VRE) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 88 Carbapenem-resistant bacteria market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 89 Flu market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 90 Respiratory syncytial virus (RSV) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 91 Candida market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 92 Tuberculosis and drug-resistant TB market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 93 Meningitis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 94 Gastrointestinal panel testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 95 Chlamydia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 96 Gonorrhea market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 97 HIV market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 98 Hepatitis C market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 99 Hepatitis B market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 100 Other infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 101 Genetic testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 102 Newborn screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 103 Predictive and presymptomatic testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 104 Other genetic testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 105 Neurological disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 106 Cardiovascular disease market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 107 Microbiology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 108 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 109 Molecular diagnostics market: Test location outlook and key takeaways
  • Fig. 110 Molecular diagnostics market: Test location movement analysis
  • Fig. 111 Point of care market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 112 Self-test or over-the-counter market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 113 Central laboratories market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 114 Molecular diagnostics market revenue, by region, 2025 & 2033 (USD Million)
  • Fig. 115 Regional marketplace: Key takeaways
  • Fig. 116 Regional marketplace: Key takeaways
  • Fig. 117 North America molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 118 Key country dynamics
  • Fig. 119 Estimated cancer incidence in U.S., 2025 - 2033
  • Fig. 120 U.S. molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 121 Key country dynamics
  • Fig. 122 Estimated cancer incidence in Canada, 2025 - 2033
  • Fig. 123 Canada molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 124 Key country dynamics
  • Fig. 125 Estimated cancer incidence in Mexico, 2025 - 2033
  • Fig. 126 Mexico molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 127 Europe molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 128 Key country dynamics
  • Fig. 129 Estimated cancer incidence in UK, 2025 - 2033
  • Fig. 130 UK molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 131 Key country dynamics
  • Fig. 132 Estimated cancer incidence in Germany, 2025 - 2033
  • Fig. 133 Germany molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 134 Key country dynamics
  • Fig. 135 Estimated cancer incidence in France, 2025 - 2033
  • Fig. 136 France molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 137 Key country dynamics
  • Fig. 138 Estimated cancer incidence in Spain, 2025 - 2033
  • Fig. 139 Spain molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 140 Key country dynamics
  • Fig. 141 Estimated cancer incidence in Italy, 2025 - 2033
  • Fig. 142 Italy molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 143 Key country dynamics
  • Fig. 144 Estimated cancer incidence in Denmark, 2025 - 2033
  • Fig. 145 Denmark molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 146 Key country dynamics
  • Fig. 148 Sweden molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 149 Key country dynamics
  • Fig. 150 Norway molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 151 Key country dynamics
  • Fig. 152 Belgium molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 153 Key country dynamics
  • Fig. 154 Switzerland molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 155 Key country dynamics
  • Fig. 156 Netherlands molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 157 Key country dynamics
  • Fig. 158 Portugal molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 159 Key country dynamics
  • Fig. 160 Turkey molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 161 Rest of Europe molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 162 Asia Pacific molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 163 Key country dynamics
  • Fig. 164 Japan molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 165 Key country dynamics
  • Fig. 167 China molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 168 Key country dynamics
  • Fig. 169 India molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 170 Key country dynamics
  • Fig. 171 Australia molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 172 Key country dynamics
  • Fig. 173 Thailand molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 174 Key country dynamics
  • Fig. 175 South Korea molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 176 Key country dynamics
  • Fig. 177 South Korea molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 178 Key country dynamics
  • Fig. 179 Malaysia molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 180 Key country dynamics
  • Fig. 181 Vietnam molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 182 Key country dynamics
  • Fig. 183 Indonesia molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 184 Rest of Asia Pacific molecular diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 185 Latin America molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 186 Key country dynamics
  • Fig. 187 Brazil molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 188 Key country dynamics
  • Fig. 189 Argentina molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 190 Key country dynamics
  • Fig. 191 Colombia molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 192 Key country dynamics
  • Fig. 193 Chile molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 194 Key country dynamics
  • Fig. 195 Peru molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 196 Key country dynamics
  • Fig. 197 Ecuador molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 198 Rest of Latin America molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 199 MEA molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 200 Key country dynamics
  • Fig. 201 Estimated cancer incidence in South Africa, 2025 - 2033
  • Fig. 202 South Africa molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 203 Key country dynamics
  • Fig. 204 Estimated cancer incidence in Saudi Arabia, 2025 - 2033
  • Fig. 205 Saudi Arabia molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 206 Key country dynamics
  • Fig. 207 Estimated new cancer cases in UAE, 2025 - 2033
  • Fig. 208 UAE molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 209 Key country dynamics
  • Fig. 210 Kuwait molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 211 Rest of MEA molecular diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 212 Key company categorization
  • Fig. 213 Global company market share analysis for molecular diagnostics, 2025
  • Fig. 214 North America company market share analysis for molecular diagnostics, 2025
  • Fig. 215 Europe company market share analysis for molecular diagnostics, 2025
  • Fig. 216 Asia Pacific company market share analysis for molecular diagnostics, 2025
  • Fig. 217 Latin America company market share analysis for molecular diagnostics, 2025
  • Fig. 218 MEA company market share analysis for molecular diagnostics, 2025
  • Fig. 219 Strategy mapping